Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
The AAPS Journal|March 22, 2022
In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static ModelsXiaoyan Chu, Grace Hoyee Chan, Robert Houle, et al.
European Journal of Clinical Pharmacology|January 26, 2019
Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairmentLuzelena Caro, Larissa Wenning, Hwa-Ping Feng, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult ParticipantsHwa-Ping Feng, Zifang Guo, Christine Fandozzi, et al.
Clinical Pharmacology in Drug Development|January 21, 2026
A Human Mass Balance and Metabolism Study of [14C]-Ubrogepant in Healthy Male AdultsRamesh R Boinpally, Joshua Rowe, Pushpa Chandrasekar, et al.
The Journal of Antimicrobial Chemotherapy|December 13, 2018
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravirHwa-Ping Feng, Zifang Guo, Lisa L Ross, et al.
European Journal of Drug Metabolism and Pharmacokinetics|December 17, 2017
Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic ImpairmentWilliam L Marshall, Hwa-Ping Feng, Larissa Wenning, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease InhibitorLuzelena Caro, Larissa Wenning, Zifang Guo, et al.
Antimicrobial Agents and Chemotherapy|October 21, 2009
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A proteaseNigel J Liverton, Steven S Carroll, Jillian Dimuzio, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil FumarateHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
Bioorganic & Medicinal Chemistry Letters|August 16, 2012
Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophreniaIzzat T Raheem, Michael J Breslin, Christine Fandozzi, et al.
Pageof 3